Nabriva Therapeutics plc Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2015 to Q4 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Nabriva Therapeutics plc quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2015 to Q4 2022.
  • Nabriva Therapeutics plc Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2022 was $123M, a 3.96% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2022 $123M +$4.69M +3.96% Dec 31, 2022 10-K 2023-04-17
Q4 2021 $119M +$2.38M +2.05% Dec 31, 2021 10-K 2023-04-17
Q4 2020 $116M +$13M +12.6% Dec 31, 2020 10-K 2023-04-17
Q4 2019 $103M +$2.35M +2.33% Dec 31, 2019 10-K 2023-04-17
Q2 2019 $106M +$22.5M +26.9% Jun 30, 2019 10-Q 2019-08-08
Q1 2019 $104M +$22.5M +27.7% Mar 31, 2019 10-Q 2019-05-10
Q4 2018 $101M +$20.7M +25.9% Dec 31, 2018 10-K 2022-03-29
Q3 2018 $96.3M +$33.5M +53.3% Sep 30, 2018 10-Q 2018-11-06
Q2 2018 $83.6M +$83.5M +141660% Jun 30, 2018 10-Q 2018-08-09
Q1 2018 $81.3M +$81.2M +139867% Mar 31, 2018 10-Q 2018-05-08
Q4 2017 $80.1M +$26M +48% Dec 31, 2017 10-K 2021-03-11
Q3 2017 $62.8M Sep 30, 2017 10-Q 2017-11-09
Q2 2017 $59K* Jun 30, 2017 10-Q 2017-08-07
Q1 2017 $58.1K* Mar 31, 2017 10-Q 2017-05-10
Q4 2016 $54.1M +$13.6M +33.7% Dec 31, 2016 10-K 2020-03-12
Q4 2015 $40.5M Dec 31, 2015 10-K 2019-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.